Loading asset research
Estrella Immunopharma Inc. Common Stock
ESLANasdaq · USD · StocksQuote as of · Exchange session not verified$0.66
-1.93%
Today
ESLA
Loading 1D prices…
Market cap
$28.7M
Volume
25.9K
52w high
$3.1552w low
$0.585Company profile
Estrella Immunopharma Inc. Common Stock
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.
Sector
Health Care
Industry
Biological Products, (No Diagnostic Substances)
Exchange
Nasdaq
Display currency
USD
Location
EmeryVille, CA, United States
Fiscal year end
1231
CIK
1844417
Session & valuation
Open$0.696
Previous close$0.673
Day high$0.72
Day low$0.66
30-day avg. volume31.2K
Outstanding shares43.5M
Diluted EPS-$0.35
Latest annual period
P/E (trailing)-1.89
P/E (forward)-2.06
Price / book-3.81
Beta0.89
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2836
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| EVAXEvaxion A/S American Depositary Share | $28.2M | $7.5M | -102.38% | -$1.00 | +0.97% | Buy |
| QNCXQuince Therapeutics Inc. Common Stock | $30.1M | $0.00 | — | -$1.68 | +2.04% | Hold |
| CVMCel-Sci Corporation Common Stock | $26.2M | $0.00 | — | -$1.76 | -0.66% | Unrated |
| ALGSAligos Therapeutics Inc. Common Stock | $32.6M | $2.2M | -1106.72% | -$2.45 | -2.06% | Buy |
| SCLXScilex Holding Company Common Stock | $35.2M | $30.3M | -1236.42% | -$36.48 | -0.79% | Unrated |